PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23360302-4	2013	Administration of the cdc2 inhibitor purvalanol A restricted compaction of the injury cavity and astrocyte infiltration into the cavity.	purvalanol B	37-47	cyclin dependent kinase 1	Homo sapiens	22-26	
20596677-8	2010	Indeed, treatment with purvalanol, a cdc2-inhibitor prevents cell cycle arrest, triggering the G2/M transition.	purvalanol B	23-33	cyclin dependent kinase 1	Homo sapiens	37-41	
15130771-5	2004	Herein we demonstrate that three 2,6,9-trisubstituted purines: olomoucine, roscovitine, and purvalanol, used at concentrations ascribed by others to potently inhibit CDKs 1, 2, and 5, are powerful triggers of death in maturing cerebellar granule neurons, assessed by loss of mitochondrial reductive capacity and differential staining with fluorescent indicators of living/dead neurons.	purvalanol B	92-102	cyclin dependent kinase 1	Homo sapiens	166-170	
12226745-12	2002	When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner.	purvalanol B	29-39	cyclin dependent kinase 1	Homo sapiens	58-62	
12226745-14	2002	We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs.	purvalanol B	54-64	cyclin dependent kinase 1	Homo sapiens	117-121